Inner Balance provides proprietary hormone replacement therapy to women experiencing perimenopausal symptoms through a direct-to-consumer telehealth model. The platform offers personalized treatment plans and ongoing support for women navigating hormonal transitions.

Inner Balance offers the first treatment on the market that comprehensively addresses all perimenopausal symptoms with a single, higher-dose bioidentical hormone replacement therapy (BHRT), Oestra. This is a significant improvement over current "microdose" treatments that only alleviate a few symptoms and often require combining multiple therapies. The medical community's perspective on HRT is evolving, with increased education dispelling previous fears stemming from a flawed 2002 study. Additionally, millennial women, who are now entering perimenopause, are demanding more personalized and effective direct-to-consumer solutions, creating a large and receptive market for Inner Balance. The team, particularly Dr. Sarah Daccarett's pioneering research and authentic "brand" in advocating for higher-dose HRT, and Ran Reske's proven go-to-market execution abilities (from his previous $1B exit with Resident), provides a strong foundation. Inner Balance also has a first-mover advantage in this newly educated market.